ChromaXome Corp., Bristol-Myers deal

The companies will apply Chroma-Xome's combinatorial biology with Bristol-Myers's microbe library to produce and screen compounds for biological activity.

ChromaXome's combinatorial biology involves splicing DNA sequences from difficult-to-access sources, such as marine organisms, into industrial microorganisms, such as E. coli, in order to express large numbers of chemicals for screening drugs. ...